BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//XIMA Media GmbH//xima_typo3_calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:entry-182@www.dkfz.de
DTSTAMP:20260929T152112Z
DTSTART:20251127T090000Z
DTEND:20251127T100000Z
SUMMARY:DDLSS Richard Vile "Oncolytic Viruses as Lymphoeditors in Cancer Im
 munotherapy"
DESCRIPTION:Richard Vile\, Ph.D.\, and his research team develop experiment
 al cancer therapies\, all based on stimulating antitumor immune responses.
  Dr. Vile's research combines in vivo and in vitro assays\, but predominan
 tly focuses in murine immune-competent models and syngeneic tumors. Althou
 gh his team has a major interest in melanoma\, they also have models of pr
 ostate cancer\, glioma and brain metastases\, and can be applied across tu
 mor sites. All of this work is intended to help patients with cancer. Dr. 
 Vile's team deliberately focuses on developing therapies that can be rapid
 ly taken to clinical trials. Accordingly\, the team works closely with the
  Mayo Clinic team\, as well as those at other U.S. hospitals and worldwide
 \, and have been directly involved in clinical trials of several oncolytic
  viruses. An ongoing clinical trial for patients with hepatocellular carci
 noma is being performed at Mayo Clinic in Arizona with a VSV the team desi
 gned to express interferon. Internationally\, Dr. Vile's research lab has 
 strong links with researchers in the UK and other countries\, to test OV i
 n patients with a range of cancers.
LOCATION:DKFZ Kommunikationszentrum\, Hörsaal
URL:https://www.dkfz.de/aktuelles/veranstaltungen/detail/140-ddlss-richard-
 vile-oncolytic-viruses-as-lymphoeditors-in-cancer-immunotherapy/a182
CATEGORIES:Vorträge und Seminare
ORGANIZER;CN="Martina Jochim":mailto:m.jochim@dkfz-heidelberg.de
STATUS:CONFIRMED
SEQUENCE:1790690401
LAST-MODIFIED:20260929T140001Z
END:VEVENT
END:VCALENDAR